1. All
  2. Commentary
  3. Headlines
    1. Everest Re Managing Through A Tough Environment


      Fri, 26 Sep 2014

      By Stephen Simpson, CFA : The reinsurance markets remain quite challenging today, as companies like Everest Re (NYSE: RE ) find themselves sandwiched between double-digit price declines in many reinsurance lines and low rates of return on their investment portfolio. Everest Re has been doing a good

    2. Fast-fashion ace Uniqlo looks to disrupt U.S. market


      Thu, 18 Sep 2014

      Uniqlo ( OTCPK:FRCOY ) aims to have 39 stores up and running in the U.S. by the middle of November as it builds out its fast-fashion brand with consumers. The company has a goal to have 200 stores in the U.S. by 2020. What to watch Though traditional rivals for Uniqlo include Zara ( OTCPK:IDEXY ),

    3. How Much Is Novartis's New Heart Failure Medicine Worth?


      Thu, 11 Sep 2014

      of its new heart failure medicine LCZ696. The company's investigational heart failure medicine was found to be superior to ACE -inhibitor enalapril on key endpoints. In all likelihood, LCZ696 will be a blockbuster drug. But how much is it worth? Robust

    4. Arch Capital Getting Attractive As Its Markets Get Less So


      Thu, 11 Sep 2014

      disciplined underwriting and strong capital management, Arch Capital's shares have underperformed peers like ACE Limited (NYSE: ACE ), RenRe (NYSE: RNR ), and XL Group (NYSE: XL ) by more than 10% on a year-to-date basis. I didn

    5. Negative outlook for reinsurers continues, says Moody's


      Tue, 9 Sep 2014

      like insurance linked securities (ILS) are having a tough year and have less scope to cut pricing. Among the reinsurers: ACE , XL , PRE , RE , RNR , AHL , ENH . AXS , ACGL , RGA , MRH , UNM , OTCPK:SSREY , GLRE , TPRE . Post your comment!

    6. Briefing docs out for upcoming Ad Comm meeting on polypill


      Mon, 8 Sep 2014

      to treat cardiovascular disease. Polypills potentially combine multiple drugs (e.g. aspirin, beta-blocker, statin, ACE -inhibitor) in one pill to treat cardiovascular disorders. ETFs: IBB , BIB , IRY , BIS , IXJ , DRGS Briefing docs Post your

    7. Novartis heart failure drug candidate beats enalapril


      Sat, 30 Aug 2014

      ever done, Novartis' (NYSE: NVS ) investigational heart failure drug candidate, LCZ696 , demonstrated superiority over the ACE -inhibitor enalapril on several key endpoints. LCZ696 reduced the risk of death from cardiovascular disease by 20%, reduced

    8. Fitch Affirms ACE Limited's Ratings; Outlook Stable


      Fri, 29 Aug 2014

      Fitch) Fitch Ratings has affirmed the ratings of ACE Limited and its subsidiaries ( ACE ). The Rating Outlook is Stable. A complete list ..... KEY RATING DRIVERS The ratings affirmation reflects ACE 's continued strong operating performance despite

    9. Cheap Canadian Drugs: Why?


      Tue, 26 Aug 2014

      profitable, they must make a total of $15 per ace to produce a 15% return on investment, $60 total or $8 in profits. Once an ace is ready for production, manufacturing each ace costs a penny. The company expects to sell 150

    10. Polaris Launches Slingshot Indicating Innovation Shows No Sign of Slowing, Raising Fair Value


      Thu, 31 Jul 2014

      categories for itself by entering entirely new territories. Most recently, we have seen this with the launch of the Ace (and now the Ace family) as well as the Slingshot. We plan to increase our fair value estimate to $164 from $155, as we expect

    « Prev12345Next »
    Content Partners